- |||||||||| Rituxan (rituximab) / Roche, Biogen
MATRix regimen for newly diagnosed primary diffuse B-cell lymphoma of the central nervous system: preliminary results (Ballroom Lawn) - Oct 29, 2019 - Abstract #SNO2019SNO_331;
Two patients were switched to MATRix after 6 cycles of methotrexate and rituximab and received 2 additional cycles that included cytarabine and thiotepa...These preliminary data suggest that the MATRix regimen in safe and highly effective in the newly diagnosed setting. However, the high early mortality in patients over 70 years in this group suggests that the regimen may be too toxic for very elderly individuals.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Trial completion date, Trial primary completion date: Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Oct 16, 2019
P2, N=101, Active, not recruiting,
It can, therefore, potentially provide an improved therapeutic alternative for MGs. Completed --> Active, not recruiting | Trial completion date: Jul 2018 --> Jul 2020 | Trial primary completion date: Jul 2018 --> Jul 2020
- |||||||||| melphalan / Generic Mfg., Cytoxan oral (cyclophosphamide oral) / Generic Mfg., etoposide IV / Generic Mfg.
Retrospective data, Journal: LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. (Pubmed Central) - Sep 27, 2019
BEAM (BCNU/carmustine, etoposide, cytarabine, and melphalan) is the most commonly used conditioning regimen for ASCT in patients with relapsed/refractory (R/R) lymphomas in Europe, whereas the CBV (cyclophosphamide, BCNU, and etoposide) regimen is also widely used in North America...Thus, in the current manuscript, we report the experience of 2 transplant centers in ASCT in R/R lymphomas with three types of conditioning: BEAM, CLV (cyclophosphamide, lomustine, etoposide) and LEAM (lomustine, etoposide, cytarabine, and melphalan), with the aim to evaluate the results of alternative conditioning regimens using lomustine (LEAM and CLV) and compare them with the standard BEAM regarding early toxicity, engraftment, and transplant related mortality (TRM)...For the BEAM arm, one patient developed grade 3 cardiac toxicity with sinus bradycardia and afterwards grade 4 with acute pulmonary edema, three patients presented a grade 3 pruritic skin rash and two patients developed grade 3 seizures. In the present study we presented the differences that were observed between BEAM, LEAM, and CLV conditioning regimens offering clinical arguments for an SCT practitioner choice in the ideal situation, but also of choice for alternative regimens in the case that one regimen cannot be used.
- |||||||||| melphalan / Generic Mfg., etoposide IV / Generic Mfg.
Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Experience (Hodgkin Lymphoma) - Sep 26, 2019 - Abstract #SOHO2019SOHO_539;
Moreover, having 2 or more prognostic factors, which includes male sex, age above 50-year old, Ann Arbor stage III-IV and B symptoms, showed to be inversely correlated to OS with 5-year OS of 74% when ≤1 and 68% when it is 2 or more.Conclusion Our data show that patients who underwent ASCT maintained very good OS and PFS beyond 8-years follow-up, which is similar to published studies. However, effectiveness of post-transplant treatment strategies should also be taken into consideration and should be studied separately to assess their correlation to PFS and OS.
- |||||||||| carmustine / generics
Journal: Eosinophilic meningitis triggered by implanted Gliadel wafers: case report. (Pubmed Central) - Aug 28, 2019
Although carmustine (Gliadel) wafers improve local tumor control and extend the overall survival in patients with malignant glioma, adverse effects have been documented...These findings strongly suggest that although extremely rare, polifeprosan (the wafer matrix) can elicit an allergic reaction. When eosinophilic meningitis is suspected after the implantation of Gliadel wafers, their immediate removal should be considered.
- |||||||||| paclitaxel / Generic Mfg.
Clinical, Review, Journal: Convection-Enhanced Delivery in Malignant Gliomas: A Review of Toxicity and Efficacy. (Pubmed Central) - Aug 22, 2019
With this treatment, patients who received CED of the chemotherapeutic agent paclitaxel and immunomodulator, oligodeoxynucleotides containing CpG motifs (CpG-ODN), experienced intolerable toxicity. Toward the end of this article, an ideal CED treatment procedure is proposed and the methods for quality assurance of the CED procedure are discussed.
- |||||||||| dexamethasone / generics, doxorubicin hydrochloride / generics, cyclophosphamide intravenous / generics
Clinical, Journal: Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency. (Pubmed Central) - Aug 17, 2019
He underwent autologous stem-cell transplantation (ASCT) with melphalan 200 mg/m as high-dose therapy in February 2011, which led to a partial response, but in December 2011, progressive disease was documented, and the patient was enrolled in a clinical trial of carfilzomib monotherapy, with stable disease for 33 cycles. In October 2014 serum M protein rose to 38.6 g/L, with 24-hour kappa light-chain urine protein excretion of 840 mg, serum creatinine of 2.1 mg/dL, and an eGFR of 41 mL/min/1.73 m. He presented to discuss ongoing treatment options.
- |||||||||| temozolomide / generics, carmustine / generics
Journal: Impact of human cytomegalovirus on glioblastoma cell viability and chemotherapy treatment. (Pubmed Central) - Aug 8, 2019
Furthermore, we conclude that the virus does not confer increased resistance to chemotherapeutic drugs in various GBM cell lines, but instead reduces tumour cell viability. These results highlight that the oncomodulatory potential of HCMV is not limited to cancer-promoting activities, but also includes adverse effects on tumour cell proliferation or survival.
- |||||||||| carmustine / generics
Journal: The computational study of the γ-Fe2O3 nanoparticle as Carmustine drug delivery system: DFT approach. (Pubmed Central) - Aug 1, 2019
The nature of the intermolecular interactions has been explored by calculation of the electron densities and their Laplacian at the bond critical points using Atoms-in-Molecule theory. Moreover, natural bond orbital analysis indicates that the Carmustine molecule can be adsorbed on the nanoparticle surface with a charge transfer from the Carmustine drug to the nanoparticle.
- |||||||||| bendamustine / SymBio, Mundipharma, Astellas, generics
Clinical, Journal: Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (Pubmed Central) - Jul 18, 2019
...It is being increasingly used in the conditioning regimen for autologous stem cell transplantation (SCT) and can be an alternative to the traditionally-used carmustine...We designed a descriptive study to evaluate bendamustine in combination with etoposide, cytarabine, and melphalan (BeEAM) in the conditioning regimen for autologous SCT...Our study showed that bendamustine is a potentially toxic agent in the conditioning regimen for autologous SCT, resulting in significant liver, kidney, and gastrointestinal toxicity. Further studies are required to assess its safety and efficacy at reduced doses.
- |||||||||| melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
P2 data, Journal: Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem-Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma. (Pubmed Central) - Jul 13, 2019
At median follow-up of 34.5 months (range, 26-72), Gem/Bu/Mel resulted in improved 2-year PFS (65% vs. 51%) (P=0.008) and overall survival (89% vs. 73%, P=0.0003). In conclusion, Gem/Bu/Mel is safe, yielding, in this nonrandomized comparison, improved outcomes compared with a concurrently treated and prognostically matched cohort of primary refractory or poor-risk relapsed HL patients receiving BEAM.
- |||||||||| Adcetris (brentuximab vedotin) / Seattle Genetics, Takeda
Clinical, Journal: Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin. (Pubmed Central) - Jul 11, 2019
Pulmonary toxicity occurred frequently in our cohort and was more common in patients who received Bv than in patients who did not receive Bv, although this was not statistically significant. Because patients with HL are exposed to a myriad of therapies with potential for pulmonary toxicity, continuing to evaluate the risk associated with Bv is critical.
- |||||||||| busulfan / Generic mfg., thiotepa / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioned Autologous Stem Cell Transplantation. (Pubmed Central) - Jul 4, 2019
We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) and 79 patients with systemic non-Hodgkin lymphoma after traditional carmustine, etoposide, cytarabine, and melphalan-conditioned ASCT (BEAM-ASCT)...Clinicians should be aware of these differences in infection risk in TBC-ASCT patients, which more closely parallel those seen in allo-HCT recipients. New prophylactic approaches to help minimize these infections should be considered in this population.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Trial suspension, Combination therapy: Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 26, 2019
P1, N=30, Suspended,
However, due to concerns of higher toxicity, Fotemustine substitution in BEAM does not seem justified, if not for easier supply. Recruiting --> Suspended
- |||||||||| Ninlaro (ixazomib) / Takeda
Enrollment closed, Enrollment change: Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma (clinicaltrials.gov) - May 23, 2019
P1, N=11, Active, not recruiting,
Our results are encouraging and justify evaluation of TECAM versus BEAM (carmustine, etoposide, cytarabine, melphalan) in a prospective multicenter study in a large homogenous patient population. Recruiting --> Active, not recruiting | N=24 --> 11
- |||||||||| Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci, Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion date: CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies (clinicaltrials.gov) - May 20, 2019
P1, N=60, Active, not recruiting,
Recruiting --> Active, not recruiting | N=24 --> 11 Trial completion date: Jun 2019 --> Jun 2020
- |||||||||| Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen
Journal: Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. (Pubmed Central) - May 17, 2019
...Blood cells were mobilised with filgrastim given for 4-5 days and collected after a median of 2 (range, 1-2) apheresis...Most subjects received carmustine, etoposide, cytarabine and melphalan (BEAM), cyclophosphamide, carmustine and etoposide (CBV) or high-dose melphalan...There was no correlation between numbers of storage days at 4 °C and viability afte storage (r = -0.018, p = 0.14)) nor rates of recovery of neutrophils (r = -0.054, p = 0.52) or platelets (r = 0.116, p = 0.14). Blood cells collected for autotransplant can be stored at 4 °C for 6 d. This method is simple, inexpensive and widely applicable.
- |||||||||| bendamustine / generics, Mundipharma, Astellas
Clinical, Journal: Bendamustine-Based conditioning prior to ASCT: Results of a French Multicenter Study of 474 Patients from LYSA Centers. (Pubmed Central) - May 17, 2019
Carmustine shortage has led to an increase use of alternative conditioning regimens prior to autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine-based (BeEAM)...Pretransplant chronic renal failure, hyperhydration volume, duration of hyperhydration, and etoposide dose were predictive factors of NRM...Drugs shortage may have dangerous consequences. Prospective, comparative studies are needed to confirm the toxicity/efficacy extents from this conditioning regimen compared to other types of high dose therapy.
- |||||||||| carmustine / Generic mfg.
Clinical, Journal: Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry. (Pubmed Central) - Apr 26, 2019
P=N/A
Implantation of biodegradable wafers impregnated with carmustine (BCNU) is one of the few chemotherapeutic modalities that have been evaluated in Phase III trials and approved by the US FDA for treatment of newly diagnosed high-grade glioma and recurrent glioblastoma...Subgroup analyses will include tumor type, molecular marker status, and treatment combinations. Interim analyses from the VIGILANT registry will be reported until complete results are available in 2024.
- |||||||||| carmustine / generics
Journal: Chloroethylating anticancer drug-induced mutagenesis and its repair in Escherichia coli. (Pubmed Central) - Apr 18, 2019
Chloroethylnitrosourea (CENU) derivatives, such as nimustine (ACNU) and carmustine (BCNU), are employed in brain tumor chemotherapy due to their ability to cross the blood-brain barrier...These results suggest that the toxic lesions induced by CENU were repaired additively or synergistically by NER and recombination. In other words, lesions, such as ICLs, appear to be repaired by NER and recombination independently.
- |||||||||| lomustine / generics, carmustine / generics
Journal: Carnosic Acid Impedes Cell Growth and Enhances Anti-cancer Effects of Carmustine and Lomustine in Melanoma. (Pubmed Central) - Apr 17, 2019
Additionally, CA can enhance BCNU- and CCNU-mediated cytotoxicity and cell cycle arrest in B16F10 cells. Finally, we find that CA inhibits tumor growth, and reduces the values of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in vivo This study concludes that CA may be safe and useful as a novel chemotherapeutic agent.
|
